Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658476 · ClinicalTrials.gov registry record · Phase 3
Omega-3 Fatty Acids for Treatment of Depression in Adolescents
A Phase 3 study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT00658476 is a Phase 3 study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT00658476, a Phase 3 study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
Adolescence is the highest risk period for depression onset. More than 1.3 million youths suffer from major depression annually in the United States, and there is evidence for an increasing trend. Because many adolescents have their first depressive episode in adolescence and adolescent depression often leads to recurrent mood disorders in adults, effective treatment during early illness can minimize the negative consequences of initial and repeated episodes. Although some antidepressants (particularly Selective serotonin reuptake inhibitors (SSRIs)) are effective treatments for juvenile depression, recent warnings about suicide and the use of SSRls highlight the need for new and safe treatment for juvenile depression. Data in adults suggest that supplementation with polyunsaturated fatty acids (PUFA) might be useful for the treatment of depression. The purpose of this study is to investigate the safety and efficacy of PUFA for the treatment of adolescent depression.
Interventions
- OTHER Placebo
- BEHAVIORAL Cognitive Behavior Therapy
- DIETARY_SUPPLEMENT Fish Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658476
The ClinicalTrials.gov registry entry for NCT00658476 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00658476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658476 about?
NCT00658476 is a clinical study titled "Omega-3 Fatty Acids for Treatment of Depression in Adolescents". Adolescence is the highest risk period for depression onset. More than 1.3 million youths suffer from major depression annually in the United States, and there is evidence for an increasing trend. Because many adolescents have their first depressive episode in adolescence and adolescent depression o...
What is the current status of trial NCT00658476?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2006-11. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00658476?
The interventions under investigation include: Placebo (OTHER), Cognitive Behavior Therapy (BEHAVIORAL), Fish Oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00658476?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.